This finding could indicate that SMAD4-negative tumor cells might be more prone to metastasize through hematogenous and lymphatic pathways despite NAT, supporting the idea that patients with SMAD4 loss are more at risk for treatment failure and recurrence. The gene discussed is BRD2; the disease is neoplasm.